Gedea Biotech AB: Company Profile
Background
Overview
Gedea Biotech AB, established in 2015, is a Swedish biotechnology company headquartered in Lund, Sweden. The company is dedicated to developing antibiotic-free treatments for vaginal infections, with a primary focus on bacterial vaginosis (BV). Their lead product, pHyph, is designed to restore and maintain a healthy vaginal microbiome, thereby promoting long-term vaginal health.
Mission and Vision
Gedea Biotech's mission is to make a sustainable contribution to global women's health by providing modern, antibiotic-free treatments for common vaginal infections. The company aims to offer women reliable, long-term solutions that are accessible when needed.
Industry Significance
The company operates within the biotechnology sector, focusing on women's health. By addressing the challenges associated with antimicrobial resistance, Gedea Biotech plays a crucial role in advancing treatments for vaginal infections, a common concern among women worldwide.
Key Strategic Focus
Core Objectives
Gedea Biotech is committed to developing and commercializing antibiotic-free treatments for vaginal infections, particularly bacterial vaginosis. The company seeks to provide effective, safe, and sustainable alternatives to traditional antibiotic therapies.
Areas of Specialization
The company's primary specialization lies in the development of treatments that restore and maintain a healthy vaginal microbiome, thereby preventing and treating bacterial vaginosis without the use of antibiotics.
Key Technologies Utilized
Gedea Biotech employs a novel mode of action that involves promoting a healthy vaginal microbiome and restoring the vaginal pH to its normal level of 4.0–4.5. This approach aims to break down the biofilm formed during BV, under which infectious bacteria thrive, thereby providing a beneficial environment for the healthy vaginal microbiome.
Primary Markets Targeted
The company primarily targets the European market, with plans to expand into the U.S. market through strategic partnerships. The focus is on women experiencing bacterial vaginosis and other vaginal infections.
Financials and Funding
Funding History
Gedea Biotech has successfully raised a total of $6.26 million across multiple funding rounds. The most recent funding activity was a grant of $2.71 million completed in February 2024.
Notable Investors
The company has secured backing from several notable investors, including the European Commission, EIT Health, and the European Union.
Utilization of Capital
The raised capital is intended to support the development and commercialization of pHyph, including clinical trials, regulatory approvals, and market entry strategies.
Pipeline Development
Key Pipeline Candidates
The lead product in Gedea Biotech's pipeline is pHyph, an antibiotic-free treatment for bacterial vaginosis.
Stages of Development
pHyph has completed Phase 2 clinical trials, demonstrating efficacy and safety in treating bacterial vaginosis. The company has initiated Phase 3 studies to further validate the product's effectiveness and to support regulatory approvals.
Target Conditions
The primary target condition for pHyph is bacterial vaginosis. The company is also exploring the treatment of vulvovaginal candidiasis (VVC) with pHyph.
Anticipated Milestones
Gedea Biotech anticipates obtaining CE marking for pHyph in 2025, which will allow for its commercialization in Europe. The company is also seeking partnerships for the U.S. market to conduct remaining clinical studies and launch the product.
Technological Platform and Innovation
Proprietary Technologies
Gedea Biotech's proprietary technology involves a natural substance known as GDA 001, which is well-documented and approved as a food additive. This substance is utilized in the formulation of pHyph to treat and prevent bacterial vaginosis.
Significant Scientific Methods
The company employs a novel mode of action that promotes a healthy vaginal microbiome, restores vaginal pH to its normal level, and breaks down the biofilm formed during BV. This approach provides a beneficial environment for the healthy vaginal microbiome without the use of antibiotics.
Leadership Team
Executive Profiles
- Annette Säfholm: CEO with a PhD in Medicine from Lund University and an executive MBA from Executive Foundation Lund (EFL). She has over 10 years of experience in project management and business development within the biotech and healthcare sectors.
- Ton Berkien: Chairman of the Board with a background in leadership, business development, and M&A. He has held positions such as Chief Business Officer at Cantargia and Ultimovacs ASA.
- Per-Ola Forsberg: CFO with a degree in business administration from Lund University. He has experience in financial management and strategic planning.
- Ulf Ellervik: Co-founder and board member, responsible for R&D and patents. He is a Professor of Bioorganic Chemistry at Lund University.
- Helena Strevens: Co-founder and board member, serving as a medical advisor. She is an Associate Professor in Obstetrics and Gynecology at Skåne University.
